KR102245354B1 - 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도 - Google Patents

백내장 수술 후 염증에서의 서방출 덱사메타손의 용도 Download PDF

Info

Publication number
KR102245354B1
KR102245354B1 KR1020157036698A KR20157036698A KR102245354B1 KR 102245354 B1 KR102245354 B1 KR 102245354B1 KR 1020157036698 A KR1020157036698 A KR 1020157036698A KR 20157036698 A KR20157036698 A KR 20157036698A KR 102245354 B1 KR102245354 B1 KR 102245354B1
Authority
KR
South Korea
Prior art keywords
dexamethasone
dosage form
formulation
unit dosage
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157036698A
Other languages
English (en)
Korean (ko)
Other versions
KR20160040471A (ko
Inventor
버논 지. 웡
윌리엄 에스. 화이트
마에 더블유. 후
글렌 티. 황
파이나 카라시나
Original Assignee
아이콘 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이콘 바이오사이언스, 인크. filed Critical 아이콘 바이오사이언스, 인크.
Publication of KR20160040471A publication Critical patent/KR20160040471A/ko
Application granted granted Critical
Publication of KR102245354B1 publication Critical patent/KR102245354B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020157036698A 2013-05-24 2014-05-23 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도 Active KR102245354B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827091P 2013-05-24 2013-05-24
US61/827,091 2013-05-24
PCT/US2014/039319 WO2014190248A1 (en) 2013-05-24 2014-05-23 Use of sustained release dexamethasone in post-cataract surgery inflammation

Publications (2)

Publication Number Publication Date
KR20160040471A KR20160040471A (ko) 2016-04-14
KR102245354B1 true KR102245354B1 (ko) 2021-04-30

Family

ID=51934201

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157036698A Active KR102245354B1 (ko) 2013-05-24 2014-05-23 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도

Country Status (9)

Country Link
US (4) US10028965B2 (enExample)
EP (2) EP3003318B1 (enExample)
JP (1) JP6530744B2 (enExample)
KR (1) KR102245354B1 (enExample)
CN (2) CN105407896B (enExample)
AU (1) AU2014268434B2 (enExample)
CA (1) CA2913336C (enExample)
ES (1) ES2902951T3 (enExample)
WO (1) WO2014190248A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2726805T3 (es) 2011-04-25 2019-10-09 Icon Bioscience Inc Guías de dosis para jeringa de inyección
EP4566638A3 (en) 2015-05-29 2025-08-27 Allergan, Inc. Implant for treatment of an ocular condition
AU2017290143A1 (en) 2016-06-30 2019-02-21 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
WO2019157198A2 (en) 2018-02-09 2019-08-15 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
WO2020168106A1 (en) 2019-02-13 2020-08-20 Notable Labs, Inc. Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer
IT201900003529A1 (it) * 2019-03-11 2020-09-11 Ntc S R L Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242099B2 (en) 2000-07-05 2012-08-14 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
WO2013036309A2 (en) * 2011-06-10 2013-03-14 Wong Vernon G Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211793A (en) 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
DE3500103C2 (de) 1985-01-04 1987-01-22 R.P. Scherer GmbH, 6930 Eberbach Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
WO1994010970A1 (en) 1992-11-09 1994-05-26 Quest International B.V. Solubilizing agents
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
WO2002000137A1 (en) 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
US20040253293A1 (en) 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
ITMI20032087A1 (it) 2003-10-27 2005-04-28 Pharmafilm S R L Film autosupportanti per uso farmaceutico ed alimentare.
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP1793803B1 (en) 2004-10-01 2012-11-07 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP2266638A3 (de) 2009-06-25 2014-08-13 Biotronik VI Patent AG Biokorrodierbares Implantat mit einer aktiven Beschichtung
US20110160645A1 (en) 2009-12-31 2011-06-30 Boston Scientific Scimed, Inc. Cryo Activated Drug Delivery and Cutting Balloons
ES2726805T3 (es) 2011-04-25 2019-10-09 Icon Bioscience Inc Guías de dosis para jeringa de inyección
AU2012325370A1 (en) 2011-06-10 2014-01-30 Ramscor, Inc. Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
ES2908977T3 (es) 2013-06-03 2022-05-04 Mcneil Ab Forma de dosificación farmacéutica sólida para liberar en la cavidad oral al menos dos ingredientes farmacéuticos activos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242099B2 (en) 2000-07-05 2012-08-14 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
WO2013036309A2 (en) * 2011-06-10 2013-03-14 Wong Vernon G Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Also Published As

Publication number Publication date
US20190105330A1 (en) 2019-04-11
WO2014190248A1 (en) 2014-11-27
JP6530744B2 (ja) 2019-06-12
US20180303851A1 (en) 2018-10-25
US10028965B2 (en) 2018-07-24
JP2016526039A (ja) 2016-09-01
AU2014268434B2 (en) 2018-11-22
EP3003318B1 (en) 2021-12-22
AU2014268434A1 (en) 2015-12-10
ES2902951T3 (es) 2022-03-30
CN105407896B (zh) 2019-08-27
US20160120879A1 (en) 2016-05-05
CN105407896A (zh) 2016-03-16
US10159683B2 (en) 2018-12-25
CN110339153A (zh) 2019-10-18
EP4082525A1 (en) 2022-11-02
CA2913336C (en) 2020-12-15
KR20160040471A (ko) 2016-04-14
EP3003318A1 (en) 2016-04-13
CA2913336A1 (en) 2014-11-27
US20230078906A1 (en) 2023-03-16
EP3003318A4 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
KR102245354B1 (ko) 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도
JP2020063236A (ja) 後眼部障害を処置するための方法およびデバイス
US11510916B2 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
JP7266108B2 (ja) 治療用抗体製剤
JP2019167376A (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
EP4185318B1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US20230295266A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
TW202400214A (zh) 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案
HK40008204A (en) Dexamethasone unit dosage form, kit and use for post-cataract surgery inflammation
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
JP2021523222A (ja) 網膜への薬剤の持続送達のための点眼剤および方法
KR20190138858A (ko) 목시플록사신이 담긴 사전 충전형 시린지

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190322

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200520

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200520

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201125

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200716

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190322

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210216

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210125

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201125

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200716

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190322

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210422

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210423

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240319

Start annual number: 4

End annual number: 4